In Clinical

Follow this topic

Bookmark

Record learning outcomes

The EMA recently recommended granting marketing authorisation for Saxenda (liraglutide) for weight management in obese adults or overweight people who have one or more weight-related complication(s), such as type 2 diabetes, hypertension, high cholesterol or obstructive sleep apnoea. Saxenda is added to a reduced-calorie diet and physical activity.

Treatment should stop if patients have not lost at least 5 per cent of their body weight after 12 weeks. The intended dose of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, for weight management is 3mg injected once a day. Liraglutide is currently approved for type 2 diabetes at doses of up to 1.8mg daily. GLP-1-based therapies may increase heart rate as well as being linked, in a small number of reports, to acute pancreatitis, gallstones and gallbladder inflammation. Saxenda's risk management plan will closely monitor these concerns.